Introduction
Introduction

The development of diabetic nephropathy (DN) is the leading cause of end-stage renal disease and is clinically characterized by proteinuria and progressive renal insufficiency [1]. It is postulated that localized oxidative stress is a key component in the development of DN
and accumulating evidence suggests, that patients with diabetes mellitus have increased rates of lipoprotein oxidation products [3, 4] . The pathogenic role of oxidized low-density lipoprotein (oxLDL) in the kidney has been studied in vitro on a variety of renal cells, like mesangial cells [5] [6] [7] , endothelial cells [8, 9] and podocytes [10] . Many [11] . Furthermore, oxLDL can harm the kidney either directly, by deposition of lipids, or indirectly, by stimulating the generation of reactive oxygen species (ROS) [12, 13] . In addition to this in vitro data, several animal models have documented that chronic exposure to oxLDL promotes collagen synthesis and activates pro-inflammatory pathways [14, 15] . Moreover, oxLDL also promotes fibrosis by stimulating synthesis and expression of TGF-␤ [16] .
important roles have been ascribed to oxLDL, which could be involved in the progression of renal diseases. It is well known that oxLDL can induce the production of chemokines and the expression of adhesion molecules on endothelial cells
Beside the important role of mesangial cells in the onset of DN [17] , accumulating data demonstrate that podocytes are functionally and structurally injured very early in the natural history of DN [18] . Therefore [19] [20] [21] [22] and beside pro-inflammatory actions of oxLDL, the cytotoxic effects of oxLDL on podocytes has been recently shown [10] . Scavenger receptors are found on many cell lineages. They are known to bind modified lipoproteins and to promote the transformation of macrophages (M⌽) and smooth muscle cells into foam cells [23, 24] . However, little is known about the regulation and function of scavenger receptors in normal and pathological states of the kidney. [25, 26] . In contrast soluble CXCL16 produced by proteolytic cleavage via ADAM10 and ADAM17 [27, 28] , acts as a chemotactic factor for CXCR6 expressing cells such as NKT and polarized T helper cells [29, 30] . Importantly, in an animal model of chronic kidney disease elevated CXCL16 levels were accompanied with increased levels of oxLDL in the onset of renal obstruction [31] . We 
CXCL16 (SR-PSOX) is one of the few scavenger receptors that is found in two distinct forms: membrane bound and soluble. Surface-expressed CXCL16 binds and internalizes oxLDL and promotes adhesion of cells expressing its cognate receptor CXCR6
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Kidney sections
Cell culture
Human conditionally immortalized podocytes were isolated and cultivated as previously described [32] . Cells 1C and D) . Again, combined blocking of CXCL16 and CD36 inhibited the uptake of oxLDL to a similar extent than CD36 alone (Fig. 1C and D) . Weak expression of CD36 in human podocytes was determined by confocal immunofluorescence analysis (Fig. 1E) . In contrast to CD36, stronger constitutive CXCL16 expression was detectable in human podocytes (Fig. 1F) Fig. 2A) . In addition, the treatment of human podocytes with TGF-␤ resulted in a strong reduction of F-actin stress fibers ( Fig. 2A) . One main receptor attaching podocytes to the glomerular basement membrane is the integrin ␣3␤1 [39] . As documented in Fig. 2B application of oxLDL down-regulated ␣3-integrin expression. Importantly, blocking surface-expressed CXCL16 significantly restored the expression of ␣3-integrin (Fig. 2B) . In addition the treatment with a CD36 specific blocking antibody led to a recovery of the ␣3-integrin expression. The most prominent influence on the ␣3-integrin expression was observed by the combined treatment with a CXCL16 and CD36 antibody (Fig. 2B) . Similar to oxLDL treatment the application of TGF-␤ also reduced ␣3-integrin expression (Fig. 2B) . To quantify the effect of oxLDL on ␣3-integrin expression, we performed FACS analysis of human podocytes 48 hrs after oxLDL treatment. OxLDL led to a 15% reduction of ␣3-integrin surface expression (Fig. 2C) . In addition, confocal fluorescence analysis revealed, that oxLDL treatment reduced ␣3-integrin expression at focal contacts, which could be restored by CXCL16 blocking antibody treatment (data not shown).
It is known that increased production of extracellular matrix from podocytes is a hallmark in DN [40] . Therefore the effect of oxLDL mediated uptake on fibronectin production was investigated.
As demonstrated in Fig. 2D , oxLDL dramatically induced fibronectin production in human podocytes. Blocking the uptake of oxLDL with antibodies against CXCL16 or CD36 significantly reduced the fibronectin production. Notably, the strongest inhibitory effect was seen with CXCL16 blocking antibody and with the combined treatment of CXCL16 and CD36 antibodies (Fig. 2D) . Again, TGF-␤ known to induce fibronectin expression was used as positive control. Fig. 3 , oxLDL significantly induced ROS production in human podocytes. Importantly, ROS production was significantly inhibited by pre-incubation of podocytes with blocking antibody against CXCL16 (Fig. 3A and B) . In addition the oxLDL-induced ROS production was also significantly inhibited by the blockage of CD36 (Fig. 3A and B) . (Fig. 3A and B) . Fig. 4A (Fig. 4D) (Fig. 4H ).
Blocking of CXCL16 and CD36 reduced oxLDL-mediated ROS production
ROS have been identified as potential major contributors to the pathogenesis of diabetic kidney disease [41]. To investigate the role of oxLDL in ROS production in human podocytes, we analysed the fluorescence intensity of ROS sensitive 5-(and-6)-chloromethyl-2Ј7Ј-dichlorodihydro-fluorescein diacetate after oxLDL and TGF-␤ treatment. As shown in
Furthermore, TGF-␤ strongly increased the amount of ROS in human podocytes
Down-regulation of ADAM10 under hyperglycaemic conditions is accompanied by the induction of CXCL16 in human podocytes
Hyperglycaemia is an important determinant in the pathogenesis of diabetic microvascular complications in both type 1 and type 2 diabetes [42]. To analyse the influence of hyperglycaemia on the expression of CXCL16 and ADAM10, human podocytes were cultured in LG (ϭ5 mM) or HG (ϭ30 mM) containing media. As documented in
and B, HG treatment led to a significant induction of cellular CXCL16 in human podocytes 24 and 120 hrs after treatment. Importantly we also noticed a down-regulation of ADAM10 expression after HG treatment at both time-points (Fig. 4A, B and C). In addition, with a CXCL16 specific ELISA we confirmed that hyperglycaemic conditions increased cellular CXCL16 expression
CXCL16 and oxLDL expression is induced in podocytes and tubular cells of streptozotocin treated mice
Decreased number in podocytes, broadening of the foot processes, and reduction of nephrin expression has been reported in animal models of type 1 diabetes [43, 44] Fig. 5A 
. To investigate the expression of CXCL16 in a STZ-induced mouse model of type 1 diabetes, we performed immunohistochemical analysis of CXCL16 in kidney sections of different time-points after induction. As shown in
and B, 17 days after STZ treatment, CXCL16 expression was significantly induced in podocytes and tubular cells. The glomerular CXCL16 expression increased over time and showed the strongest induction 50 days after STZ injection
Fig. 1 Involvement of CXCL16 and CD36 in the uptake of oxLDL. (A) DiI-oxLDL uptake was analysed after the pre-treatment of podocytes with an IgG control antibody (control), a CXCL16 blocking antibody (ϩC16 Ab), a CD36 blocking antibody (ϩCD36 Ab), or both antibodies (ϩC16 Ab ϩ CD36 Ab
Germany). (F) Podocytes were fixed with methanol and incubated with CXCL16 antibodies followed by Alexa 488 coupled secondary antibodies (green). Cells were than incubated with DAPI to visualize nuclei (blue). Fluorescence analyses were performed with a LSM 510 Meta confocal laser-scanning microscope (Carl Zeiss).
( Fig. 5A) . In addition, immunohistochemical analysis of oxLDL in mouse kidney sections revealed that oxLDL expression was also induced in STZ-treated mice (Fig. 5C) . Notably, no oxLDL expression could be seen in kidneys of control mice (Fig. 5C) .
In biopsies of patients with DN increased glomerular CXCL16 was accompanied by high levels of oxLDL
To further investigate the expression of CXCL16, ADAM10 and oxLDL in kidney sections of patients we DN, we performed immunofluorescence analysis. As documented in Fig. 6 increased CXCL16 expression was mainly found in podocytes (Fig. 6B) . Interestingly, increased glomerular CXCL16 expression was accompanied with lower levels of ADAM10 (Fig. 6A and B) . In contrast, the amount of ADAM10 in tubuli was not significantly changed between normal kidneys and patients with DN (Fig. 6A) . In addition in glomeruli and tubuli of kidney biopsies of patients with DN increased levels of oxLDL were detectable (Fig. 6C and D) . (Fig. 6E, yellow colour) was observed in glomeruli of DN patients, assuming that CXCL16 represents a scavenger receptor for oxLDL also in vivo. [45] . Several interventions have been shown to slow down the progression of DN, but unfortunately they cannot prevent the disease [46] . Improved therapeutic treatment of DN is urgently needed but is hampered due to the incomplete understanding of the complex mechanism of the disease. In this context podocytes seem to be an attractive target of research. It is commonly 3816 accepted that podocytes are an early target of injury in the onset of DN and therefore may be the major culprit of the disease. Interestingly a link between oxLDL and the injury of podocytes has been already described [10] . In contrast the scavenger receptors responsible for the uptake of oxidized LDL in podocytes have been so far not characterized. We have recently shown that human podocytes constitutively express the scavenger receptor CXCL16 (Gutwein et al., unpublished data) . Notably in our current study we identified CXCL16 and CD36 as the main receptors for the uptake of oxLDL in podocytes and in tubular cells respectively.
To investigate if CXCL16 may be responsible for oxLDL accumulation in glomeruli of DN patients, we performed double immunofluorescense analysis of CXCL16 and oxLDL in biopsies of DN patients. Importantly, co-localization of CXCL16 and oxLDL
Discussion
DN is the leading cause of end-stage renal failure and is clinically characterized by proteinuria und progressive renal insufficiency
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Fig. 2 Role of CXCL16 and CD36 in the oxLDL-induced regulation of F-actin, ␣3-integrin and fibronectin expression in human podocytes. Immunofluorescence analyses of F-Actin stress fibers (A), ␣3-integrin (B) and fibronectin expression (D) in human podocytes 48 hrs after oxLDL (100 g/ml) treatment in the presence of 10 g/ml IgG control antibody (control/ oxLDL), 10 g/ml CXCL16 blocking antibody (oxLDLϩC16Ab), 5 g/ml CD36 blocking antibody (oxLDLϩCD36Ab) or the combination of both antibodies (oxLDLϩC16AbϩCD36Ab). Treated human podocytes grown on cover slips were fixed with 4% paraformaldehyde/PBS solution and blocked with 1% bovine serum albumin/0.2 Triton-X-100/PBS. The cells were stained with DAPI to visualize the nuclei, with Alexa 594 conjugated Phalloidin to visualize the F-actin stress fibers (red fluorescence) and with an Alexa 488 coupled secondary antibodies to visualize ␣3-integrin (green) and fibronectin (green). (C) ␣3-integrin surface expression was investigated by FACS analysis 48 hrs
It is well accepted that the number of podocytes is reduced in animal models of DN [47] and in biopsies of patients with early and late DN [20, 21] . The exact aetiology for the reduction in the number of podocytes in diabetes remains speculative, but two mechanisms have been suggested: apoptosis and cell detachment. It has been recently shown that oxLDL is able to induce apoptosis in murine podocytes [10] . In contrast in our study oxLDL did not lead to apoptosis in human podocytes. The effects induced by oxLDL can differ due to the kind of LDL, its degree of oxidative modification, the amount of oxLDL and on the type of target cell involved [48] . The discrepancy in the above mentioned study and our observations could be explained by an increased sensitivity of mouse podocytes to the cytotoxicity of oxLDL. Furthermore strongly oxidized LDL often exerts a cytotoxic effect, whereas minimally oxidized LDL causes more subtle alteration in vascular cell functions [48] . Currently, we investigate the effects of [50] and it is able to degrade collagen IV [51] . Therefore down-regulation of ADAM10 in vivo could participate in the development of membrane thickening, known to be a characteristic feature of DN [52] [52] . Beside this our study presents evidence that CXCL16 mediated uptake of oxLDL induced ROS production in podocytes. In addition, it is known that hyperglycaemic conditions can lead to ROS production in podocytes [53] and together with increased CXCL16 expression it could lead to a vicious circle which leads to high levels of ROS production in glomeruli of diabetic patients. [54] . In addition, the preferential binding of oxLDL into rat glomeruli has been reported already a long time ago [55] . Furthermore the accumulation of oxLDL in biopsies of patients with kidney diseases has been also demonstrated [56] . Notably, plasma levels of oxLDL were significantly elevated in patients with DN [57] .
In summary our findings, that CXCL16 is a major scavenger receptor for oxLDL in human podocytes and that CXCL16 and oxLDL are early up-regulated in the onset of DN, highlight both molecules as new therapeutic targets in DN.
